G2gbio (KRX: 456160)
Who is buying G2gbio?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩4.7bn ($4M) of G2gbio, the 106th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net bought ₩2.6bn ($2M) and retail investors net bought ₩1.9bn ($1M) over the same window. Foreigners were net buyers on 11 of the 20 sessions.
Foreign investors hold 5.15% of G2gbio's listed shares (KRX ownership data as of Oct 13, 2026), down from 5.54% twenty sessions earlier and 1.72% a year ago.
The stock closed at ₩33,150 on Oct 13, 2026: -5.29% over 20 sessions, -50.52% year-to-date, -47.60% over one year. The 52-week range is ₩22,400 – ₩124,000.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩33,150 | +₩1.2bn | ₩-4.4bn | +₩3.1bn |
| 2026-10-12 | ₩37,500 | +₩2.0bn | ₩-3.7bn | +₩1.6bn |
| 2026-10-08 | ₩42,000 | ₩-2.0bn | +₩0.8bn | +₩1.2bn |
| 2026-10-07 | ₩44,700 | ₩-2.7bn | +₩0.4bn | +₩1.3bn |
| 2026-10-06 | ₩43,900 | ₩-3.3bn | +₩2.0bn | +₩1.1bn |
| 2026-10-02 | ₩43,600 | ₩-1.0bn | +₩2.2bn | ₩-0.7bn |
| 2026-10-01 | ₩43,500 | ₩-0.2bn | +₩8.2bn | ₩-7.6bn |
| 2026-09-30 | ₩35,350 | +₩0.1bn | +₩0.5bn | ₩-0.6bn |
| 2026-09-29 | ₩33,900 | ₩-1.3bn | +₩1.6bn | ₩-0.2bn |
| 2026-09-28 | ₩34,750 | +₩1.4bn | +₩1.8bn | ₩-3.2bn |
| 2026-09-23 | ₩32,050 | +₩0.3bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-22 | ₩31,900 | +₩0.6bn | ₩-0.8bn | +₩0.4bn |
| 2026-09-21 | ₩32,100 | +₩0.3bn | +₩0.2bn | ₩-0.4bn |
| 2026-09-18 | ₩31,900 | ₩-0.6bn | ₩-0.3bn | +₩0.9bn |
| 2026-09-17 | ₩33,000 | +₩0.1bn | +₩0.2bn | ₩-0.4bn |
| 2026-09-16 | ₩33,000 | ₩-1.6bn | ₩-0.2bn | +₩1.5bn |
| 2026-09-15 | ₩34,500 | ₩-2.6bn | +₩0.3bn | +₩2.5bn |
| 2026-09-14 | ₩31,600 | +₩1.2bn | ₩-1.3bn | +₩0.1bn |
| 2026-09-11 | ₩33,000 | +₩1.6bn | ₩-2.3bn | +₩0.7bn |
| 2026-09-10 | ₩34,200 | +₩1.7bn | ₩-2.5bn | +₩0.8bn |
| 2026-09-09 | ₩35,000 | +₩0.9bn | ₩-2.3bn | +₩1.3bn |
| 2026-09-08 | ₩37,250 | +₩0.0bn | ₩-0.5bn | +₩0.5bn |
| 2026-09-07 | ₩38,300 | +₩0.4bn | +₩0.4bn | ₩-0.8bn |
| 2026-09-04 | ₩37,950 | +₩0.2bn | +₩0.6bn | ₩-0.8bn |
| 2026-09-03 | ₩35,900 | ₩-0.1bn | +₩0.1bn | +₩0.0bn |
| 2026-09-02 | ₩37,050 | +₩1.2bn | ₩-1.4bn | +₩0.1bn |
| 2026-09-01 | ₩38,600 | ₩-0.4bn | ₩-1.6bn | +₩2.0bn |
| 2026-08-31 | ₩41,350 | ₩-3.0bn | ₩-1.8bn | +₩5.2bn |
| 2026-08-28 | ₩43,650 | ₩-1.8bn | +₩2.4bn | +₩0.2bn |
| 2026-08-27 | ₩41,250 | ₩-2.0bn | +₩2.0bn | +₩0.6bn |
| 2026-08-26 | ₩41,750 | +₩1.4bn | +₩0.8bn | ₩-1.6bn |
| 2026-08-25 | ₩37,500 | ₩-0.8bn | +₩0.4bn | +₩0.7bn |
| 2026-08-24 | ₩37,950 | +₩2.6bn | ₩-0.9bn | ₩-0.8bn |
| 2026-08-21 | ₩37,400 | ₩-0.6bn | ₩-0.3bn | +₩0.9bn |
| 2026-08-20 | ₩40,950 | ₩-3.4bn | +₩1.4bn | +₩2.8bn |
| 2026-08-19 | ₩41,050 | +₩0.4bn | +₩1.7bn | ₩-0.6bn |
| 2026-08-18 | ₩40,150 | +₩2.1bn | ₩-0.3bn | ₩-1.2bn |
| 2026-08-14 | ₩44,100 | ₩-1.7bn | +₩2.3bn | +₩0.9bn |
| 2026-08-13 | ₩42,600 | ₩-1.8bn | +₩0.7bn | +₩0.9bn |
| 2026-08-12 | ₩41,750 | ₩-2.3bn | +₩2.6bn | ₩-0.3bn |
| 2026-08-11 | ₩41,300 | ₩-3.2bn | +₩2.8bn | +₩0.3bn |
| 2026-08-10 | ₩42,350 | ₩-2.3bn | +₩4.5bn | ₩-1.9bn |
| 2026-08-07 | ₩37,200 | +₩0.0bn | +₩0.1bn | ₩-0.2bn |
| 2026-08-06 | ₩37,800 | ₩-3.7bn | +₩0.7bn | +₩3.0bn |
| 2026-08-05 | ₩36,850 | ₩-1.2bn | ₩-0.0bn | +₩1.7bn |
| 2026-08-04 | ₩36,650 | ₩-5.2bn | +₩3.0bn | +₩1.9bn |
| 2026-08-03 | ₩30,650 | ₩-1.2bn | +₩0.4bn | +₩0.4bn |
| 2026-07-31 | ₩26,950 | +₩1.0bn | ₩-0.3bn | ₩-0.7bn |
| 2026-07-30 | ₩22,950 | +₩1.5bn | ₩-0.7bn | ₩-0.9bn |
| 2026-07-29 | ₩24,150 | +₩1.6bn | ₩-1.0bn | ₩-0.7bn |
| 2026-07-28 | ₩27,450 | ₩-0.5bn | +₩0.1bn | +₩0.4bn |
| 2026-07-27 | ₩30,600 | ₩-1.0bn | +₩0.0bn | +₩0.9bn |
| 2026-07-24 | ₩31,000 | ₩-1.1bn | +₩0.4bn | +₩0.6bn |
| 2026-07-23 | ₩30,300 | +₩1.5bn | ₩-0.2bn | ₩-1.4bn |
| 2026-07-22 | ₩28,150 | +₩0.5bn | ₩-0.4bn | +₩0.0bn |
| 2026-07-21 | ₩28,300 | +₩1.4bn | ₩-1.8bn | +₩0.4bn |
| 2026-07-20 | ₩29,100 | ₩-0.2bn | ₩-0.3bn | +₩0.5bn |
| 2026-07-16 | ₩31,300 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-07-15 | ₩32,650 | +₩1.1bn | ₩-0.2bn | ₩-0.9bn |
| 2026-07-14 | ₩30,350 | +₩0.1bn | +₩0.6bn | ₩-0.8bn |
| 2026-07-13 | ₩31,650 | ₩-0.1bn | +₩1.2bn | ₩-1.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩1.2bn | +$1M | ₩-4.4bn | +₩3.1bn |
| 5 days | ₩-4.8bn | $-4M | ₩-5.0bn | +₩8.4bn |
| 20 days | ₩-4.7bn | $-4M | +₩2.6bn | +₩1.9bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying G2gbio stock?
Over the last 5 sessions foreign investors net sold ₩4.8bn ($4M) of G2gbio; over 60 sessions they net sold ₩24.2bn ($18M); since Jan 1, 2026 they net bought ₩53.5bn ($40M). Over 20 sessions the stock is the 106th largest foreign net sale among 1828 KOSDAQ stocks.
How much of G2gbio do foreign investors own?
Foreign investors own 5.15% of G2gbio's shares as of Oct 13, 2026, versus 1.72% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩2.6bn ($2M) and retail investors net bought ₩1.9bn ($1M) of G2gbio. Foreign selling is being absorbed mainly by retail buying.
Is G2gbio listed on KOSPI or KOSDAQ?
G2gbio (지투지바이오) trades on KOSDAQ under KRX code 456160 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2024 | ₩1bn ($1M) | – | -₩11bn (-$8M) | -₩83bn (-$62M) |
| 2025 | ₩0bn ($0M) | -45.00% | -₩12bn (-$9M) | -₩12bn (-$9M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.